{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T15:26:41Z","timestamp":1786807601243,"version":"build-2736575974"},"reference-count":52,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Patient Care and STDs"],"abstract":"<jats:p>Pre-exposure prophylaxis (PrEP) uptake remains low among Black immigrant populations in the United States. Limited data exist on determinants of PrEP uptake in this population. Guided by the Consolidated Framework for Implementation Research (CFIR), we explored potential determinants of PrEP uptake among Black immigrants in New England. We conducted in-depth interviews with Black immigrants from Africa and the Caribbean, recruited through a safety-net health care system in New England between December 2024 and August 2025. Eligibility included age \u2265 18 years, residing in Massachusetts, living in the United Sates for \u2264 5 years, PrEP eligible, and willing to discuss HIV and sexual health. Interviews were conducted in participants\u2019 preferred language. Guided by CFIR, we conducted a thematic analysis using NVivo to identify key themes. Of the 20 participants, 70% were female with a mean age of 36.5 (standard deviation [SD] = 7.5) years, 60% were partnered, and 60% were from the Caribbean. The mean US residence was 18.1 months (SD = 10.7). We identified themes across CFIR domains: (1) innovation characteristics (fear of daily medications and side effects), (2) outer setting (cultural\/religious barriers, HIV stigma, competing basic needs, and immigration fears), (3) inner setting (health care trust and language barriers), (4) individual characteristics (low perceived HIV risk, PrEP misconceptions), and (5) process (lack of culturally-tailored PrEP information delivery). Black immigrants face unique barriers to PrEP uptake across CFIR domains, including individual beliefs, cultural factors, health care systems, and implementation processes. The results highlight the need for culturally responsive PrEP implementation strategies that target these determinants.<\/jats:p>","DOI":"10.1177\/10872914261470149","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T08:19:00Z","timestamp":1785572340000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Determinants of PrEP Uptake Among Black African and Caribbean Immigrants in New England: A Qualitative Analysis Using the Consolidated Framework for Implementation Research"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-233X","authenticated-orcid":false,"given":"Sylvia","family":"Shangani","sequence":"first","affiliation":[{"name":"Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizze","family":"Kiptui","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kimball","sequence":"additional","affiliation":[{"name":"Boston Medical Center, Boston, Massachusetts, USA."},{"name":"Chobanian &amp; Avedisian School of Medicine, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"A. Assoumou","sequence":"additional","affiliation":[{"name":"Boston Medical Center, Boston, Massachusetts, USA."},{"name":"Chobanian &amp; Avedisian School of Medicine, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rodriguez-Diaz","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0033354920942623"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101661"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.9046"},{"key":"e_1_3_2_5_1","unstructured":"4.Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences. Massachusetts HIV Epidemiologic Profile Statewide Report\u2014Data as of 1\/1\/2024 June 2024. Available from: https:\/\/www.mass.gov\/lists\/hivaids-epidemiologic-profiles [Last accessed: February3 2026]."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.1343"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205"},{"key":"e_1_3_2_9_1","unstructured":"8.U.S. Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 update: A clinical practice guideline. Centers for Disease Control and Prevention. 2021. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/112360 [Last accessed: May30 2025]."},{"key":"e_1_3_2_10_1","unstructured":"9.US Public Health Services. Preexposure prophylaxis for the prevention of HIV infection in the United States-2021 Update. 2021. Available from: https:\/\/stacks.cdc.gov\/view\/cdc\/112360 [Last Accessed: April 14 2026]."},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01963-9"},{"key":"e_1_3_2_12_1","unstructured":"11.U.S. Food & Drug Administration. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention [Last accessed: March7 2026]."},{"key":"e_1_3_2_13_1","unstructured":"12.Gilead Sciences. Yeztugo\u00ae (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection. GILEAD; 2025. Available from: https:\/\/www.gilead.com\/news\/news-details\/2025\/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection [Last accessed: October30 2025]."},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3018(25)00036-0"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100738"},{"key":"e_1_3_2_16_1","unstructured":"15.AIDSVu. AIDSVu Releases New Data Highlighting Ongoing Inequities in PrEP Use among Black and Hispanic People and across Regions of the Country. 2023. Available from: https:\/\/aidsvu.org\/news-updates\/news-updates-aidsvu-releases-new-data-highlighting-ongoing-inequities-in-prep-use-among-black-and-hispanic-people-and-across-regions-of-the-county\/ [Last accessed: April18 2026]."},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10903-012-9691-6"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40615-022-01256-z"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10903-023-01515-z"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2025.0043"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02843-z"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2067-8"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2017.1300633"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1521\/aeap.2022.34.3.209"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10903-019-00873-x"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01245-0"},{"key":"e_1_3_2_27_1","unstructured":"26.U.S. Citizenship and Immigration Services. Citizenship resource center. Available from: https:\/\/www.uscis.gov\/citizenship\/learn-about-citizenship\/citizenship-and-naturalization\/i-am-a-lawful-permanent-resident-of-5-years [Last accessed: April18 2026]."},{"key":"e_1_3_2_28_1","unstructured":"27.Tamir CAM. One-in-Ten Black People Living in the U.S. Are Immigrants. Pew Research Center. Pew Research Center; 2022."},{"key":"e_1_3_2_29_1","unstructured":"28.Center for Disease Control and Prevention. Updated. Clinical guidance for PrEP. HIV NexusMarch 5. 2025. Available from: https:\/\/www.cdc.gov\/hivnexus\/hcp\/prep\/index.html [Last accessed: May20 25]."},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1525822X05279903"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114523"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732316665344"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1071\/sh20175"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2025.0020"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/ijwh.S129355"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-021-03159-2"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-8127-9"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1353\/hpu.0.0001"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/08964289.2019.1585324"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02670-x"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2023.0117"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2024.0190"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-017-1972-6"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-03023-9"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0330698"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.2196\/59800"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0000000000002974"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2016.1201196"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02631-4"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-6301-0"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1188\/25.Onf.371-381"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40615-023-01617-2"}],"container-title":["AIDS Patient Care and STDs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261470149","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10872914261470149","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914261470149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:46:50Z","timestamp":1786805210000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10872914261470149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":52,"alternative-id":["10.1177\/10872914261470149"],"URL":"https:\/\/doi.org\/10.1177\/10872914261470149","relation":{},"ISSN":["1087-2914","1557-7449"],"issn-type":[{"value":"1087-2914","type":"print"},{"value":"1557-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"article-number":"10872914261470149"}}